|
| |
 |
Molecular
Diagnostics Laboratory is selected as one of the eight sites by the
National Cancer Institute-sponsored Clinical Assay Validation Network
(CAVN), 2010
|
|
k-ras mutational analysis
is nor available for monitoring anti-cancer therapies, 2010
|
|
Molecular
Diagnostics Laboratory is selected as one of the twelve sites
by NHLBI to participation as a clinical site for the
“Randomized Clinical Trial of Genotype Guided Dosing of Warfarin
Therapy”, 2009-2012
|
|
Polyoma BK viral load real-time PCR test is available for monitoring
kidney transplantation, 2009
|
|
Molecular
Diagnostics Laboratory is selected by the National Cancer
Institute-sponsored Early Detection Research Network (EDRN) as the
Biomarker Reference Laboratory (BRL), 2005
|
|
We now offer a new improved
Cystic Fibrosis (CF) test to detect the 25 most common
CFTR gene mutations as recommended the American College of Obstetrics and
Gynecology (ACOG). July, 2005
|
|
Molecular Diagnostics Laboratory is selected by NCI to
become a Quality Control/Quality Assurance Laboratory for an Early Detection
Research Network’s (EDRN) validation study designed to test Microsatellite DNA
in urine sediment as a marker for recurrence of bladder cancer, November, 2004
|
|
Molecular Diagnostics Laboratory is
selected by NCI as a Reference Laboratory for the Cancer Marker National
Network, October, 2004
|
|
Dr. Richard Y. Zhao from Northwestern University Feinberg School of
Medicine and Chicago Children's Memorial Hospital assumes the new
directorship of the Molecular Diagnostics Laboratory on September 1, 2004
|
|
